制药公司GSK宣布了一系列战略性举措，以加强其研发能力并改善财务表现。[1]该公司将投资4亿英镑在剑桥建设新的研发中心，同时关闭历史悠久的斯蒂文斯工厂，并将大部分科学家迁至新地点。[1]
为了支撑增长目标，GSK承诺到2029年削减19亿英镑的年度成本。[1]公司预计今年将能够将20种以上的潜在药物推进至后期试验阶段，相比之下去年这一数字仅为10种。[1]
GSK面临关键专利到期风险：其主力HIV药物dolutegravir约占集团销售额的五分之一，专利将在2028年至2030年期间到期。[1]公司目标在2031年实现400亿英镑以上的收入。[1]首席执行官Luke Miels从今年初开始担任职务，去年该公司还完成了近80亿美元收购美国癌症专家公司Nuvalent的交易。[1]
GlaxoSmithKline has announced a £400 million investment to construct a new research and development center in Cambridge, marking a strategic shift in the pharmaceutical company's operational footprint [1]. The move will involve closing the historic Stevenage facility and relocating the majority of its scientific workforce [1].
The investment is coupled with an ambitious cost-reduction program, with GSK targeting £1.9 billion in annual cost cuts by 2029 [1]. Despite these efficiency measures, the company projects it can maintain or grow profit margins during the critical 2028-30 period when patents on its HIV drug dolutegravir—which accounts for approximately one-fifth of group sales—are set to expire [1]. GSK aims to achieve revenues exceeding £40 billion by 2031 [1]. Chief Executive Luke Miels, who assumed the role at the start of this year, is overseeing these strategic initiatives [1].
The company also disclosed plans to advance more than 20 potential drugs into late-stage trials this year, compared with 10 in the previous year [1]. This pipeline expansion follows GSK's acquisition of American cancer specialist Nuvalent for nearly $800 million last year [1].